Share Price | Terns Pharmaceuticals, Inc. Stock Analysis & Recommendation

Q: What does Terns Pharmaceuticals, Inc. do?

Overview: Terns Pharmaceuticals, Inc. operates in the Pharmaceuticals & Biotechnology industry and is classified as a micro-cap company.Financial Snapshot: Net Profit: -24 Million (Quarterly Results - Mar 2025) Market Cap: USD 340.62 Million (Micro Cap)Key Metrics: P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: -1.02 Return on Equity: -27.72% Price to Book: 1.04Contact Details: Details: No Company Details Available Registrar Address: Not available.

Q: Is Terns Pharmaceuticals, Inc. overvalued or undervalued?

As of 27 March 2023, the valuation grade for Terns Pharmaceuticals, Inc. has moved from risky to does not qualify, indicating a significant downgrade in its investment appeal. The company appears to be overvalued given its current metrics, with a Price to Book Value of 0.99 and an EV to EBIT of 0.10, suggesting that the market may not be accurately reflecting the company's underlying value. Additionally, the Return on Capital Employed (ROCE) is exceptionally high at 1332.80%, but the Return on Equity (ROE) is negative at -27.72%, indicating potential issues with profitability.In comparison to its peers, Terns Pharmaceuticals has a P/E ratio of -3.7684, while Scholar Rock Holding Corp. and Edgewise Therapeutics, Inc. have P/E ratios of -11.1959 and -10.4346, respectively, both indicating a challenging environment for valuation. The recent stock performance shows a decline of 49.1% over the past year compared to a 10.26% increase in the S&P 500, reinforcing the notion that Terns Pharmaceuticals is struggling relative to broader market trends. Overall, the combination of negative ratios and poor stock performance suggests that the company is overvalued at its current price of $3.68.

Q: Is Terns Pharmaceuticals, Inc. technically bullish or bearish?

As of 26 September 2025, the technical trend for Terns Pharmaceuticals, Inc. has changed from mildly bullish to bullish. The weekly MACD is bullish, and both the weekly and monthly Bollinger Bands are bullish, indicating positive momentum. The daily moving averages also support a bullish stance. However, the monthly KST is bearish, and the monthly OBV is mildly bearish, suggesting some caution. In terms of performance, Terns Pharmaceuticals has outperformed the S&P 500 over the past week and month, with returns of 1.46% and 5.38% compared to -0.31% and 2.75% for the index, respectively. However, over the past year, the stock has underperformed the S&P 500, with a return of -13.67% against 15.64%. Overall, the current technical stance is bullish, with moderate strength driven by positive indicators, despite some mixed signals in longer-term metrics.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

1.58 M

Shareholding (Sep 2025)

FII

12.47%

Held by 75 FIIs

DII

44.59%

Held by 32 DIIs

Promoter

21.90%

How big is Terns Pharmaceuticals, Inc.?

22-Jun-2025

As of Jun 18, Terns Pharmaceuticals, Inc. has a market capitalization of 340.62 million and reported net sales of 0.00 million with a net profit of -90.40 million for the latest four quarters. Shareholder's funds are at 345.87 million and total assets at 363.93 million as of Dec 24.

View full answer

What does Terns Pharmaceuticals, Inc. do?

22-Jun-2025

Terns Pharmaceuticals, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, currently reporting a net loss of $24 million and a market cap of $340.62 million. Key financial metrics include a negative P/E ratio, no dividend yield, and a return on equity of -27.72%.

View full answer

Is Terns Pharmaceuticals, Inc. overvalued or undervalued?

25-Jun-2025

As of March 27, 2023, Terns Pharmaceuticals, Inc. is considered overvalued with a valuation downgrade to "does not qualify," reflected by a negative P/E ratio of -3.7684, a significant decline in stock performance, and concerning profitability metrics, indicating poor investment appeal at its current price of $3.68.

View full answer

Is Terns Pharmaceuticals, Inc. technically bullish or bearish?

30-Sep-2025

As of September 26, 2025, Terns Pharmaceuticals, Inc. shows a bullish technical trend with positive momentum indicators, although caution is advised due to mixed longer-term signals and underperformance over the past year compared to the S&P 500.

View full answer

Compare Terns Pharmaceuticals, Inc. with Similar Stocks

Renovaro, Inc.MaxCyte, Inc.bluebird bio, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 3,898 Million ()

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-1.04

Return on Equity

-33.24%

Price to Book

13.72

Revenue and Profits:

Net Sales:

(Quarterly Results - Jun 2025)

Net Profit:

-24 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

102.75%

6 Months

514.61%

1 Year

681.86%

2 Years

599.8%

3 Years

270.83%

4 Years

731.53%

5 Years

0.0%

Terns Pharmaceuticals, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

-100.00%

EBIT Growth (5y)

-210.58%

EBIT to Interest (avg)

-73.74

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.02

Sales to Capital Employed (avg)

0.01

Tax Ratio

0.28%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

100.00%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

0.99

EV to EBIT

0.10

EV to EBITDA

0.10

EV to Capital Employed

1.37

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

1332.80%

ROE (Latest)

-27.72%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Bullish

RSI

No Signal

Bearish

Bollinger Bands

Bullish

Moving Averages

Mildly Bullish (Daily)

KST

Bullish

Dow Theory

Mildly Bearish

No Trend

OBV

Mildly Bullish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Majority shareholders

Strategic Entities

Domestic Funds

Held in 40 Schemes (21.04%)

Foreign Institutions

Held by 75 Foreign Institutions (12.47%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -6.17% vs -26.82% in Jun 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-27.30",
          "val2": "-25.30",
          "chgp": "-7.91%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-24.10",
          "val2": "-22.70",
          "chgp": "-6.17%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 1.44% vs -49.59% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-101.00",
          "val2": "-101.70",
          "chgp": "0.69%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-88.90",
          "val2": "-90.20",
          "chgp": "1.44%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY

Jun'25

Jun'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-27.30

-25.30

-7.91%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-24.10

-22.70

-6.17%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is -6.17% vs -26.82% in Jun 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-101.00

-101.70

0.69%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-88.90

-90.20

1.44%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 1.44% vs -49.59% in Dec 2023

All Annual Results

Company CV

About Terns Pharmaceuticals, Inc.

Terns Pharmaceuticals, Inc.

Pharmaceuticals & Biotechnology

No Details Available.

Company Coordinates

No Company Details Available

Terns Pharmaceuticals, Inc.

1Day

52 Week

CASH

FII

DII

Promoter

How big is Terns Pharmaceuticals, Inc.?

Watch in Real-Time

What does Terns Pharmaceuticals, Inc. do?

Is Terns Pharmaceuticals, Inc. overvalued or undervalued?

Is Terns Pharmaceuticals, Inc. technically bullish or bearish?

Compare Terns Pharmaceuticals, Inc. with Similar Stocks

MarketsMojo — Loved in India, Now Global

Dashboard

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY

Annual Results Snapshot (Consolidated) - Dec'24

About Terns Pharmaceuticals, Inc.

Company Coordinates